Abstracts tagged "COVID-19"

Abstract Number: 1549 • ACR Convergence 2021
Experience from a Diverse Rheumatology Cohort with COVID-19: Are We Doing Better Than We Expected?
Michael Grant¹, Matas Orentas², Sobia Hassan¹, Sonali Khandelwal¹, Donyea Moore³ and Najia Shakoor¹, ¹Rush University, Chicago, IL, ²RUMC, Chicago, IL, ³Rush University Medical Center, Chicago, IL
Background/Purpose: The COVID-19 pandemic has been particularly concerning for patients with rheumatologic conditions because they are potentially predisposed to more severe outcomes. Studies have suggested…
Abstract Number: 1590 • ACR Convergence 2021
Sleep Disturbance Improves with SARS-COV2 Vaccinations in Patients with Rheumatologic and Chronic Inflammatory Diseases
Niti Pawar¹, Kimberly E. Taylor¹, Monica Yang¹, Parakkal Deepak², Wooseob Kim², Michael Paley³, Mehrdad Matloubian¹, Alex Carividi¹, Matthew Ciorba², Emanuel Demissie¹, Alia A. El-Qunni,², Katherine Huang², Baylee Kinnett², Lily E. McMorrow², Diana Paez¹, Abbey Rose², Rebecca E. Schriefer², Ali H Ellebedy², Alfred Kim², Mary Nakamura⁴, Patricia Katz¹ and Lianne Gensler⁵, ¹University of California San Francisco, San Francisco, CA, ²Washington University School of Medicine, St. Louis, MO, ³Washington University in St. Louis, Olivette, MO, ⁴UCSF/SFVAHCS, San Francisco, CA, ⁵Department of Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: As the COVID-19 pandemic unfolded, people across the world experienced a psychological burden with social confinement, concerns about health, potential infection, jobs, financial difficulty,…
Abstract Number: 1607 • ACR Convergence 2021
The Impact of Health Literacy and Numeracy on COVID-19 Vaccine Hesitancy in SLE
Rebecca Sadun¹, Mithu Maheswaranathan¹, Megan Clowse², Kai Sun¹, Jennifer Rogers¹, Jayanth Doss¹, Lisa Criscione-Schreiber³ and Amanda Eudy¹, ¹Duke University, Durham, NC, ²Duke University, Chapel Hill, NC, ³Duke University School of Medicine, Durham, NC
Background/Purpose: The ACR has issued guidance recommending COVID-19 vaccine for all patients with rheumatic diseases. Vaccine hesitancy research prior to the COVID-19 pandemic has demonstrated…
Abstract Number: 1719 • ACR Convergence 2021
Pandemic-Associated Complications in Pregnant Women with Rheumatic Diseases
Diana Johnson, Hiral Dave, Yunjun Luo and Christina Chambers, University of California San Diego, La Jolla, CA
Background/Purpose: Pregnant women with rheumatic diseases may have been particularly vulnerable to the various consequences of the current pandemic, whether or not they were infected…
Abstract Number: L07 • ACR Convergence 2020
Tocilizumab for COVID-19 Infection: A Randomized, Double-Blind, Placebo-Controlled Trial
John Stone¹, ¹Massachusetts General Hospital, Boston, MA
Background/Purpose: The efficacy of interleukin-6 receptor blockade in hospitalized COVID-19 patients not on mechanical ventilation is unclear.Methods: We performed a randomized, double-blind, placebo-controlled trial in…
Abstract Number: L01 • ACR Convergence 2020
Outcomes of COVID-19 Infection in Patients with Rheumatic Diseases in a Multicenter Healthcare System: A Comparative Cohort Study
Naomi Serling-Boyd¹, Kristin D'Silva¹, Tiffany Hsu², Xiaoqing Fu³, Rachel Wallwork⁴, April Jorge¹, Yuqing Zhang¹, Ellen Gravallese⁵, Hyon K. Choi⁶, Jeffrey Sparks⁷ and Zachary Wallace⁸, ¹Massachusetts General Hospital, Boston, MA, ²Brigham and Women's Hospital, Jamaica Plain, MA, ³Mass General Hospital, Boston, MA, ⁴Johns Hopkins Hospital, Baltimore, MA, ⁵Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁶MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ⁷Brigham and Women's Hospital, Boston, MA, ⁸Massachusetts General Hospital, Newton, MA
Background/Purpose: The risk of poor outcomes from COVID-19 among rheumatic disease patients compared to the general population remains poorly understood. Filling this knowledge gap is…
Abstract Number: L02 • ACR Convergence 2020
Risk Mitigating Behavior in People with Rheumatic Diseases or Psoriasis During the COVID-19 Pandemic Differ by Immunosuppressant Treatment Type: A Patient survey Study
Mark Yates¹, Satveer Mahil¹, Sinead Langan², Claudia De la cruz³, Paola diMeglio¹, Nick Dand¹, Zenas Yiu⁴, Kayleigh Mason⁴, Teresa Tsakok¹, Freya Meynall⁵, Helen McAteer⁶, John Weinman¹, Paolo Gisondi⁷, Luis Puig Sanz⁸, Richard Warren⁴, Francesca Capon¹, Jullien Denis⁹, Tiago Torres¹⁰, Chris Griffiths⁴, Jonathan Barker¹, Kimme Hyrich⁴, Andrew Cope¹, Ian Bruce⁴, Iain McInnes¹¹, Raj Sengupta¹², Helena Marzo-Ortega¹³, Matthew Brown¹, James Galloway¹ and Catherine Smith¹, ¹King's College London, London, United Kingdom, ²London School of Hygiene and Tropical Medicine, London, United Kingdom, ³University of Santiago, Santiago, Chile, ⁴University of Manchester, Manchester, United Kingdom, ⁵Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom, ⁶Psoriasis Association, London, United Kingdom, ⁷University of Verona, Verona, Italy, ⁸Hospital de la Santa Creu I Sant Pau, Barcelona, Spain, ⁹Hospices Civils de Lyon, Lyon, France, ¹⁰University of Porto, Porto, Portugal, ¹¹University of Glasgow, Glasgow, United Kingdom, ¹²Royal United Hospitals Bath, Bath, United Kingdom, ¹³University of Leeds, Leeds, United Kingdom
Background/Purpose: Clinician-reported registry data suggest that use of biologics in people with immune-mediated inflammatory diseases (IMIDs) is associated with a lower risk of adverse COVID-19…
Abstract Number: L05 • ACR Convergence 2020
DMARD Changes for Patients with Rheumatoid Arthritis in the US During the First Three Months of the COVID-19 Pandemic
Kaleb Michaud¹, Sofia Pedro², Kristin Wipfler³, Ekta Agarwal⁴ and Patricia Katz⁵, ¹University of Nebraska Medical Center and Forward, the National Databank for Rheumatic Diseases, Omaha, NE, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ⁴Pfizer inc, Princeton Jct, NJ, ⁵UCSF, Mill Valley, CA
Background/Purpose: To understand medication and clinical care changes by patients with RA during the first 3 months (March through May 2020) of the COVID-19 pandemic…
Abstract Number: 0008 • ACR Convergence 2020
COVID-19 Infection Among Patients with Rheumatic Disease on Biologic & Targeted Therapies: A Systematic Review
Akhil Sood¹, Arbi Galestanian¹, Vijaya Murthy², Emilio Gonzalez¹ and Mukaila Raji¹, ¹University of Texas Medical Branch, Galveston, TX, ²University of Texas Medical Branch, League City, TX
Background/Purpose: Information about the outcomes of patients with rheumatic disease with SARS-CoV-2 infection is scarce. Patients with rheumatic disease on immunosuppressive medications might represent a…
Abstract Number: 0069 • ACR Convergence 2020
Identification of CD13 as a Potential Cause for SARS-CoV-2-triggered Hyperinflammation and Thrombosis
Eliza Pei-Suen Tsou¹, Gautam Sule¹, Mikel Gurrea Rubio², M. Asif Amin¹, Yu Zuo¹, Jason Knight¹, Yogendra Kanthi³ and David Fox¹, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, University of Michigan, Canton, MI, ³Division of Cardiovascular Medicine, Ann Arbor
Background/Purpose: The ectopeptidase CD13, which is highly expressed on stromal and myeloid cells in joints, lung and other tissues, is a known receptor for many…
Abstract Number: 0468 • ACR Convergence 2020
Concerns and Health-Related Behaviors During the COVID-19 Pandemic in Patients with or Without Autoimmune Rheumatic Disease in a Large Physician Network
Michael George¹, Shilpa Venkatachalam², Shubhasree Banerjee¹, Joshua Baker¹, Peter Merkel¹, David Curtis³, Kelly Gavigan⁴, Maria (Maio) Danila⁵, Daniel Kirby⁶, George Munoz⁷, William Sunshine⁸, William Nowell⁹ and Jeffrey R Curtis¹⁰, ¹University of Pennsylvania, Philadelphia, PA, ²Global Healthy Living Foundation, Upper Nyack, ³Global Healthy Living Foundation, New York City, ⁴Global Healthy Living Foundation, Upper Nyack, NY, ⁵University of Alabama at Birmingham (UAB), Birmingham, AL, ⁶AARA, Charlotte, NC, ⁷AARA, Aventura, FL, ⁸AARA, Boca Raton, FL, ⁹Global Healthy Living Foundation, New York City, NY, ¹⁰Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Patients with autoimmune rheumatic diseases (ARD) may be particularly concerned about COVID-19. We aimed to compare concerns and health-related behaviors of patients with common…
Abstract Number: 0623 • ACR Convergence 2020
Cytokine Storm: Outcomes in SARS-CoV-2 Patients Treated with Biologics in a Rheumatology Cohort
Neha Chiruvolu¹, Muntarin Karim², Patil Injean³, Sandy Lee³, Karina Torralba⁴, Christina Downey³, Mehrnaz Hojjati⁵, Loomee Doo⁵, Donna Jose⁶, Deepa Panikkath³, Micah Yu⁵, Anna Lafian⁵, Marven Cabling⁵ and Vaneet Sandhu⁷, ¹UC Riverside School of Medicine, Riverside, CA, ²Loma Linda University Health System, Loma Linda, CA, ³Loma Linda University Medical Center, Redlands, CA, ⁴Loma Linda University School of Medicine, Redlands, CA, ⁵Loma Linda University Medical Center, Loma Linda, CA, ⁶Loma Linda University Medical Center, Ontario, CA, ⁷Loma Linda University, Loma Linda, CA
Background/Purpose: Cytokine Release Syndrome (CRS) or Macrophage Activation Syndrome (MAS) is a life threating hyperinflammatory condition that can complicate rheumatic disease as well as infections…
Abstract Number: 1140 • ACR Convergence 2020
How Did SARS-CoV2/COVID-19 Pandemic Affected Patients with Rheumatic Diseases in Latin America? A Regional Survey from PANLAR
Daniel Fernández-Ávila¹, Julián Barahona-Correa¹, Diana Romero-Alvernia¹, Sergio Kowalski², Ana María Sapag Durán³, Antonio Cachafeiro Vilar⁴, Belia Lucía Meléndez Muñoz⁵, Carlos Santiago Pastelín⁶, Claudia Ramírez⁷, Daniel Palleiro Rivero⁸, Diego Alejandro Jaimes⁹, Dina María Arrieta¹⁰, Guillermo Pons-Estel¹¹, Jossiell Then Báez¹², Manuel Ugarte-Gil¹³, Mario Cardiel¹⁴, Nelly Colman¹⁵, Nilmo Chávez Pérez¹⁶, Paula Burgos¹⁷, Rubén Montufar¹⁸, Sayonara Sandino¹⁹, Yurilis Fuentes-Silva²⁰ and Enrique Soriano²¹, ¹Pontificia Universidad Javeriana - Hospital Universitario San Ignacio, Bogota, Colombia, ²Unidad de Investigación PANLAR. Universidade Federal do Paraná, Paraná, Brazil, ³Hospital Universitario Japonés, Santa Cruz, Bolivia, ⁴Pacífica Salud - Hospital Punta Pacífica,, Ciudad de Panamá, Panama, ⁵Hospital de la Policía Nacional N1 Quito, Quito, Ecuador, ⁶Instituto Hondureño de la Seguridad Social, Tegucigalpa, Honduras, ⁷Organización Keralty, Bogota, ⁸Instituto Nacional de Reumatología del Uruguay - Universidad de la República, Montevideo, Uruguay, ⁹Clínicos IPS- Universidad de la Sabana, Bogotá D.C., Colombia, ¹⁰Hospital México, San José de Costa Rica, Costa Rica, ¹¹Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ¹²Hospital Metropolitano de Santiago (HOMS), Santiago, Dominican Republic, ¹³Servicio de Reumatología. Hospital Nacional Guillermo Almenara Irigoyen and Universidad Científica del Sur, Lima, Peru, ¹⁴Centro de Investigación Clínica de Morelia, Morelia, Mexico, ¹⁵Hospital de Clínicas - Universidad Nacional de Asunción, Asunción, Paraguay, ¹⁶Instituto Guatemalteco de Seguridad Social, Ciudad de Guatemala, Guatemala, ¹⁷Universidad Católica de Chile, Santiago de Chile, Chile, ¹⁸Consultorio de Especialidades del Instituto Salvadoreño del Seguro Social, San Salvador, El Salvador, ¹⁹Policlínica Nicaragüense, Managua, Nicaragua, ²⁰Centro Clínico Universitario de Oriente - Universidad de Oriente, Ciudad Bolivar, Venezuela, ²¹Department of Public Health, Instituto Universitario, Escuela de Medicina Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, Capital Federal, Buenos Aires, Argentina
Background/Purpose: Social isolation during SARS-CoV-2/COVID-19 pandemic has undermined follow-up of patients with rheumatic diseases. These patients face a critical dilemma between the risk of exposure…
Abstract Number: 1576 • ACR Convergence 2020
Acute Respiratory Viral Adverse Events During Use of Antirheumatic Disease Therapies: A Scoping Review
Adam Kilian¹, Yu Pei Eugenia Chock², Irvin Huang³, Elizabeth Graef⁴, Laura Upton⁵, Aneka Khilnani⁶, Sonia Silinsky Krupnikova⁷, Ibrahim Almaghlouth⁸, Laura Cappelli⁹, Ruth Fernandez-Ruiz¹⁰, Brittany Frankel³, Jourdan Frankovich¹¹, Carly Harrison¹², Bharat Kumar¹³, Kanika Monga¹⁴, Jorge Rosario Vega¹¹, Namrata Singh¹⁵, Jeffrey Sparks¹⁶, Elaine Sullo⁶, Kristen Young¹⁷, Ali Duarte-Garcia¹⁸, Michael Putman¹⁹, Sindhu Johnson²⁰, Jean Liew³ and Aruni Jayatilleke²¹, ¹George Washington University, Washington, DC, ²Yale School of Medicine, Greenwich, CT, ³University of Washington, Seattle, WA, ⁴Beth Israel Deaconess Medical Center, Boston, MA, ⁵Georgetown University School of Medicine, Washington, DC, ⁶The George Washington University School of Medicine and Health Sciences, Washington, DC, ⁷The George Washington University School of Medicine and Health Sciences, Rockville, MD, ⁸King Saud University, Riyadh, Saudi Arabia, ⁹Johns Hopkins School of Medicine, Baltimore, MD, ¹⁰New York University School of Medicine, New York, ¹¹Temple University, Philadelphia, PA, ¹²Lupus Chat, NA, ¹³University of Iowa Hospitals and Clinics, Iowa City, IA, ¹⁴UT Health Rheumatology, HOUSTON, TX, ¹⁵University of Washington, Bellevue, WA, ¹⁶Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ¹⁷University of Texas Southwestern Medical Center, Dallas, TX, ¹⁸Mayo Clinic, Rochester, MN, ¹⁹Northwestern University, Chicago, IL, ²⁰University of Toronto, Toronto, ON, Canada, ²¹Section of Rheumatology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA
Background/Purpose: COVID-19 threatens the health of people worldwide, although it remains unclear to what extent antirheumatic disease therapies increase susceptibility to complications of viral respiratory…
Abstract Number: 0009 • ACR Convergence 2020
Prevalence of Hydroxychloroquine and Chloroquine Side Effects in Rheumatology Patients: A Retrospective Survey of 115 Cases
Zakaria El Ouali¹, Elie Bassa¹, Abdoul-Rahamane Halidou Idrissa¹, Sarah Tazi¹, Samy Housbane², Mohamed Bennani Othmani², Kawtar Nassar¹ and Saadia Janani¹, ¹Department of Rheumatology, University Hospital of Ibn Rochd, Casablanca, Morocco, Casablanca, Grand Casablanca, Morocco, ²Medical Informatics Laboratory, Faculty of Medicine and Pharmacy, University Hassan II, Casablanca, Morocco, Casablanca, Grand Casablanca, Morocco
Background/Purpose: Antimalarial drugs (ADs), including chloroquine (CQ) and hydroxychloroquine (HCQ), have anti-inflammatory, immunomodulatory, antiparasitic, anti-thrombotic, and antiviral properties. Their indications in rheumatology have been known…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.